Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325:491

We have reported therapeutic effectiveness of pharmacological stimulation of 2 adrenoreceptors (ARs) to attenuate the car-diac remodeling and myocardial infarction (MI) expansion in a rat model of dilated cardiomyopathy (DCM) post-MI. Further-more, the combination of 2 AR stimulation with 1 AR block-ade exceeded the therapeutic effectiveness of 1 AR blockade. However, these studies were relatively short (6 weeks). In this study, in the same experimental model, we compared different effects, including survival benefit, of combined therapy with the 1 AR blocker, metoprolol, plus the 2 AR agonist, fenotero